echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lai Mei Pharmaceutical was sued again for impotence "magic medicine" triggering a series of cases

    Lai Mei Pharmaceutical was sued again for impotence "magic medicine" triggering a series of cases

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 17, Lai Mei Pharmaceutical announced that its wholly-owned subsidiary Lai Mei Pharmaceutical received legal documents sent by the Changchun New District Court.
    Haiyue Pharmaceutical sued Lai Mei Pharmaceutical and Lai Mei Pharmaceutical, and froze Lai Mei Pharmaceutical.
    51.
    4575 million yuan of funds in the bank account of the industry
    .

    01 Profitable from experience pack sales?

    01 Profitable from experience pack sales?

    In February 2019, Lai Mei Pharmaceutical announced that its subsidiary Lai Mei Pharmaceutical and Haiyue Pharmaceutical signed the "Tadalafil Tablet Licensing Agreement in China" (hereinafter referred to as the "Authorization Agreement"), and obtained Haiyue Pharmaceutical's first domestic license agreement.
    The exclusive sales agency of "Tadalafil Tablets", a new drug imitated for the treatment of erectile dysfunction (ED), in China
    .

    Haiyue Pharmaceutical announced in August 2020 that the company stated in the "Purchase and Sales Contract" that it would give Tadalafil Tablets (Xinweige) experience packs at a ratio of 1:1 based on the number of deliveries from Lai Mei Pharmaceutical.
    Promote the market development work of Laimei Pharmaceutical.
    .
    .
    Help Laimei Pharmaceutical reduce investment and gain market share with practical actions
    .

    In the current contract, Haiyue Pharmaceutical presented Lamei Medicine Tadalafil Tablets (Xinweige) with a market value of more than 33 million yuan in proportion
    .

    However, in the follow-up sales process, Haiyue Pharmaceutical believed that Laimei Pharmaceutical did not give away the tadalafil tablets it donated to consumers, but sold it at a certain sales price, with a cumulative sales of 51.
    4575 million yuan, so it requested This part of the sales is paid to Haiyue Pharmaceutical
    .

    In the announcement, Lai Mei Pharmaceutical stated that all transactions conducted by Lai Mei Pharmaceutical in this case were real transactions with commercial substance, and there was no illegal sales
    .

    02 Laimei and Haiyue sued each other

    02 Laimei and Haiyue sued each other

    In fact, due to the dispute over the termination of the contract for the agency sales of tadalafil tablets, the subsidiary of Laimei Pharmaceutical previously sued Haiyue Pharmaceutical and was counter-sued by Haiyue Pharmaceutical
    .

    In February 2019, Changchun Haiyue granted Chongqing Laimei the exclusive sales agency rights for the newly approved tadalafil generic drugs in China
    .

    According to the agreement: the annual sales task volume is determined by both parties through negotiation.
    If Chongqing Laimei meets the agreed requirements every year in the first three years, it will obtain the permanent exclusive sales agency right of authorized products in China
    .

    However, after only one year of cooperation, in May 2020, the two parties had a conflict; Haiyue Pharmaceutical planned to cancel the exclusive sales rights of Lai Mei Pharmaceutical in China on the grounds that Lai Mei Pharmaceutical did not meet the task goals agreed in the contract
    .


    However, Lai Mei Pharmaceutical believes that Haiyue Pharmaceutical's acquisition of tadalafil tablets is inconsistent, and its participation in the national centralized drug procurement bidding in January 2020, etc.


    For this reason, the two parties finally "come to court".
    First, Lai Mei Pharmaceutical sued Haiyue Pharmaceutical, demanding the return of 50 million yuan for the transfer of sales rights; then Haiyue Pharmaceutical countersued Lai Mei Pharmaceutical, requiring Lai Mei Pharmaceutical to compensate for the economic losses caused by the breach of contract.
    160 million yuan
    .

    In the end, the court ruled in October 2021 to rescind the "Authorization Agreement" signed by the two parties, Haiyue Pharmaceutical returned 37.
    5 million yuan of the transfer of sales rights of Lai Mei Pharmaceutical, and Lai Mei Pharmaceutical compensated Haiyue Pharmaceutical for 37.
    5 million yuan in loss of profits
    .

    However, Lai Mei Pharmaceutical refused to accept this and filed an appeal, requesting that Haiyue Pharmaceutical should return the full amount of the transfer fee of RMB 50 million in accordance with the law, and Haiyue Pharmaceutical should be commuted to compensation of RMB 20.
    4346 million
    .

    In November 2021, Chongqing Laimei and Changchun Haiyue expressed their dissatisfaction with the first-instance judgment and appealed to the Jilin Provincial Higher People's Court
    .

    Chongqing Laimei asked Changchun Haiyue to pay 50 million yuan for the transfer of sales rights in full, and at the same time sentenced Changchun Haiyue Pharmaceutical to compensate for losses of 20.
    4346 million yuan; Changchun Haiyue requested that it should not return the sales rights transfer payment of 37.
    5 million yuan in accordance with the law
    .

    Lai Mei Pharmaceutical's announcement on the evening of February 17 this year is based on this series of matters
    .

    03 Donation of prescription drugs is expressly prohibited

    03 Donation of prescription drugs is expressly prohibited

    The latest case progress announcement of Lai Mei Pharmaceutical Co.
    , Ltd.
    shows that in the "Civil Complaint" submitted by Changchun Haiyue, the sales plan of tadalafil tablets may have involved "experiential package donation", that is, prescription drug donation, and this behavior It is expressly prohibited by the "Measures for the Supervision and Administration of Drug Circulation"
    .

    In the sales planning of this prescription drug, there has been a promotional design of experience and gifts, but this obviously does not meet the regulations in the "Measures for the Supervision and Administration of Drug Circulation"
    .


    The "Measures for the Supervision and Administration of Drug Circulation" clearly stipulates that "drug production and business enterprises shall not give prescription drugs or Class A non-prescription drugs to the public by means of tying sales, buying drugs as gifts, buying commodities as gifts, etc.


    Lamei Pharmaceutical emphasized in the announcement that all transactions conducted by Chongqing Lamei in this case were real transactions with commercial substance, and there was no illegal sales
    .


    The implication is that there is no experience pack gift for Tadalafil sold by him


    However, this is the unilateral rhetoric of Laimei Pharmaceuticals
    .


    After all, Changchun Haiyue's latest lawsuit is based on the premise that there is a gift ratio of experience equipment, and the relevant sales are recovered


    At present, the case has not yet been heard.


    The outside world has any questions about whether Chongqing Laimei has illegal sales, whether Changchun Haiyue's "donated drugs" are used as sales drugs as the total sales amount, and whether the "purchase and sales contract" between the two companies violates relevant laws and regulations, etc.


    Reference: Enterprise Announcement Interface News

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.